Study shows ibrutinib superior to traditional chemotherapy in untreated chronic leukemia patients

(University of Texas M. D. Anderson Cancer Center) A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.